Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-05-05
1993-12-21
Schenkman, Leonard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514282, 514812, A61K 3144, A61K 31495
Patent
active
052721493
ABSTRACT:
Method of treating addiction in a subject, such as a human being, by administering, to the subject, a succession of therapeutic agents. Each of these agents competes with the addictive agent for receptor binding sites, and each is administered in an amount sufficient to remove addictive agent from the subject. At least one of these therapeutic agents controls withdrawal symptoms. The method is continued until at least one of the indicated therapeutic agents fails to evoke withdrawal symptoms in the subject.
REFERENCES:
patent: 4457933 (1984-07-01), Gordon et al.
patent: 4464378 (1984-08-01), Hussain
patent: 4661492 (1987-04-01), Lewis et al.
patent: 4670459 (1987-06-01), Sjoerdsma
patent: 4800209 (1989-01-01), Sjoerdsma
patent: 4803208 (1989-02-01), Pasternak
patent: 4935428 (1990-06-01), Lewis
Lever et al., "Chapter 6. Analgesics, Opioids, and Opioid Receptors", Ann. Rep. Med. Che., vol. 18, pp. 51-60, (1983).
Dole et al., "Successful Treatment of 750 Criminal Addicts", J. Am. Med. Assn., vol. 206, No. 12, pp. 2708-2711, Dec. 16, (1968).
Dole et al., "Methadone Treatment of Randomly Selected Criminal Addicts", New Engl. J. Med., vol. 280, No. 25, pp. 1372-1375, Jun. 19, (1969).
Johnson et al., "Use of Buprenorphine in the Treatment of Opiate Addiction. I. Physiologic and Behavioral Effects During a Rapid Dose Induction", Clin. Pharmacol. Ther., vol. 46, No. 3, pp. 335-343, Sep. (1989).
Charney et al., "The Combined Use of Clonidine and Naltrexone as a Rapid, Safe, and Effective Treatment of Abrupt Withdrawl From Methadone", Am. J. Psychiatry, vol. 143, No. 7, pp. 831-837, Jul. (1986).
Brewer et al., "Opioid Withdrawl and Naltrexone Indcution in 48-72 Hours with Minimal Drop-out, Using a Modification of the Naltrexone-Clonidine Technique", Brit. J. of Psych., vol. 153, pp. 340-343. (1988).
LandOfFree
Symptom controlled receptor substitution for addiction withdrawl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Symptom controlled receptor substitution for addiction withdrawl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Symptom controlled receptor substitution for addiction withdrawl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-309199